Can Artificial Intelligence Help Find Better Medicines?
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
You may also be interested in...
Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.
Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.
Manufacturers must ensure there are commercial outlets for the products they are developing, given the speed of change in medtech markets. That was the key message for companies and innovators at the UK Med-Tech Expo Conference 2017.